Boya Liao

Dr. Boya Liao


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
YXYang Xiao
Yang Xiao
LSLingling Shu
Lingling Shu
XWXiaoping Wu
Xiaoping Wu
YLYang Liu
Yang Liu
LCLai Yee Cheong
Lai Yee Cheong
AXand Aimin Xu
and Aimin Xu
Both innate and adaptive immune cells are critical players in autoimmune destruction of insulin-producing β cells in type 1 diabetes. However, the early pathogenic events triggering the recruitment and activation of innate immune cells in islets remain obscure. Here we show that circulating fatty acid binding protein 4 (FABP4) level was significantly elevated in patients with type 1 diabetes and their first-degree relatives and positively correlated with the titers of several islet autoantibodies. In nonobese diabetic (NOD) mice, increased FABP4 expression in islet macrophages started from the neonatal period, well before the occurrence of overt diabetes. Furthermore, the spontaneous development of autoimmune diabetes in NOD mice was markedly reduced by pharmacological inhibition or genetic ablation of FABP4 or adoptive transfer of FABP4-deficient bone marrow cells. Mechanistically, FABP4 activated innate immune responses in islets by enhancing the infiltration and polarization of macrophages to proinflammatory M1 subtype, thus creating an inflammatory milieu required for activation of diabetogenic CD8 + T cells and shift of CD4 + helper T cells toward Th1 subtypes. These findings demonstrate FABP4 as a possible early mediator for β cell autoimmunity by facilitating crosstalk between innate and adaptive immune cells, suggesting that pharmacological inhibition of FABP4 may represent a promising therapeutic strategy for autoimmune diabetes.

12 May 2022 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
LGLeiluo Geng
Leiluo Geng
BLBoya Liao
Boya Liao
LJLeigang Jin
Leigang Jin
JYJiasui Yu
Jiasui Yu
XZXiaoyu Zhao
Xiaoyu Zhao
AXand Aimin Xu
and Aimin Xu

11 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
BLBoya Liao
Boya Liao
KLKin-Ho Aaron Lee
Kin-Ho Aaron Lee
FMFei Meng
Fei Meng
JWJiangwei Wu
Jiangwei Wu
JYJinghan Yang
Jinghan Yang
Sau Ching Stanley WONGSau Ching Stanley WONG
Sau Ching Stanley WONG
Cardiac pain is difficult to diagnose and treat in part because existing models fail to capture human neuro-cardiac signaling. This review examines how iPSC-derived cardiomyocytes and sensory neurons in co-culture and organoid systems model ischemic and neuro-immune mechanisms, and how such platforms enable regenerative and neuromodulatory translation. We identify key barriers (maturation, heterogeneity, scalability, safety) and propose priorities to bridge discovery and clinical application.

11 July 2026 in Neuropharmacology
Verified
Journal Article
Open access
JLJingjing LIU
Jingjing LIU
FMFei Meng
Fei Meng
BLBoya Liao
Boya Liao
CGChris Kwan Yin Gu
Chris Kwan Yin Gu
JLJessica Aijia Liu
Jessica Aijia Liu
Sau Ching Stanley WONGSau Ching Stanley WONG
Sau Ching Stanley WONG
Postoperative pain remains a major perioperative challenge, with undermanagement leading to delayed recovery, poor patient satisfaction, morbidity and the potential development of chronic pain. Perioperative dietary intake, such as a high-fat diet (HFD), has emerged as an essential regulator of postoperative pain sensitivity. While long-term HFD induces direct neuronal sensitization to prolong pain responses, the impact of short-term HFD on perioperative pain and its underlying mechanisms is yet to be characterized. Here, we investigated the role of short-term HFD intervention in postoperative pain using the hindpaw incision (HPI) model in male mice. Pain behavioral tests showed that two weeks of HFD exposure significantly prolonged mechanical and thermal nociceptive responses in HPI compared to the normal diet. Mechanistically, short-term HFD disrupted lipid metabolic homeostasis, which dysregulated the local immune microenvironment. It shifted macrophage polarization from anti-inflammatory M2 to pro-inflammatory M1 phenotype and upregulated pro-nociceptive cytokines (e.g., TNF-α, IL-6) in the incised paw tissues. Notably, SerpinB6, a key mediator linking lipid metabolism to immune regulation, was downregulated by short-term HFD. Local restoration of SerpinB6 normalized macrophage polarization, reduced pro-inflammatory cytokines (IL-6, TNF-α), and alleviated pain hypersensitivity. Furthermore, SerpinB6 exerted its effect by restoring Sirt1 expression and attenuating ERK phosphorylation. Collectively, our findings revealed that short-term HFD primed acute postoperative pain via SerpinB6 protein downregulation and subsequent immune microenvironment dysregulation. This study highlighted that short-term dietary intervention and SerpinB6 are potential therapeutic strategies for perioperative pain management.

Verified
Journal Article
Open access
PDF file
BLBoya Liao
Boya Liao
ALAaron Kin-Ho Lee
Aaron Kin-Ho Lee
ZGZheng Gu
Zheng Gu
FMFei Meng
Fei Meng
JWJiangwei Wu
Jiangwei Wu
Sau Ching Stanley WONGSau Ching Stanley WONG
Sau Ching Stanley WONG
Cardiac-related pain, including angina pectoris and pain accompanying myocardial infarction, remains clinically important, and existing treatments are inadequate for some patients. Animal and primary-tissue studies provide important mechanistic evidence, but species differences and limited access to patient-matched human neuro-cardiac tissue constrain translation. This review synthesizes the following separate advances relevant to future human iPSC-based cardiac-pain modeling: molecular mechanisms that may be reconstructed in vitro; platforms ranging from two-dimensional cultures to proposed sensory-innervated three-dimensional and microfluidic systems; and potential applications in target validation, patient-specific modeling, and analgesic screening. We distinguish direct human iPSC evidence from findings obtained in animal, primary-cell, cardiac-only, autonomic-neuron, or non-cardiac pain models. We also discuss maturation, standardization, and regulatory challenges. iPSC technologies may complement existing models and support mechanism-focused, patient-stratified research, but direct validation in human sensory–neuron–cardiac systems remains limited.

1 September 2026 in Stroke
Verified
Journal Article
Closed access
BLBoya Liao
Boya Liao
FZFang Zhang
Fang Zhang
CHChang Han
Chang Han
XYXinyao Yi
Xinyao Yi
ZZZiyi Zhang
Ziyi Zhang
WJWei Jia
Wei Jia
BACKGROUND: Alterations in circulating amino acid profiles have been observed in ischemic stroke patients; however, whether cerebral ischemia disrupts amino acid metabolism within brain tissue and whether this disruption contributes to cellular stress and cerebral injury remain unknown. This hypothesis-testing study investigates disrupted BCAA (branched-chain amino acid) catabolism as a key mechanism of ischemic brain damage and evaluates BCKDK (branched-chain α-keto acid dehydrogenase kinase) as a novel therapeutic target. METHODS: Mouse primary cortical neurons subjected to oxygen-glucose deprivation and brain tissue from a mouse acute ischemic stroke model were used as experimental systems. Untargeted metabolomics and metabolic flux analysis were used to characterize BCAA metabolism in both models. In vivo pharmacological inhibition or in vitro knockdown of BCKDK was performed using BT2 (3,6-dichlorobenzo[b]thiophene-2-carboxylic acid) treatment or RNA interference. Primary outcome variables included infarct volume, BCKDH (branched-chain α-keto acid dehydrogenase) enzyme activity, neuronal viability, and markers of energy metabolism and glutamate excitotoxicity. Between-group differences were evaluated using 1-way ANOVA; data are presented as mean ± SD with 95% CIs and corresponding P values. RESULTS: Metabolomics analysis of oxygen-glucose deprivation-exposed primary neurons revealed impaired BCAA catabolism and significant BCAA accumulation compared with normoxic controls. In ischemic mouse brain tissue, BCKDH activity was significantly suppressed, and BCKDK expression was markedly upregulated relative to sham-operated animals. Both pharmacological and genetic suppression of BCKDK substantially reduced cerebral ischemic injury, as evidenced by decreased infarct volume and improved neuronal survival (95% CI and P values per comparison). Mechanistically, ischemia-induced BCKDK expression via HIF-1α (hypoxia-inducible factor 1α)-mediated transcriptional activation, which inhibited BCAA conversion to tricarboxylic acid cycle substrates, thereby potentiating energy deficiency and glutamate excitotoxicity. CONCLUSIONS: These data identify BCKDK as a novel hypoxia-responsive factor whose upregulation drives disrupted BCAA catabolism as a key mechanism of ischemic neuronal injury. BCKDK represents a promising therapeutic target for cerebral ischemia, directly supported by both in vitro and in vivo experimental evidence presented here.